Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 10/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21175717 | 0.88 | HDAC6 (0.71) | HDAC6HDAC4HDAC1HDAC8 | |
| SCHEMBL29625977 | 0.85 | HDAC4 (0.63) | HDAC6HDAC4HDAC1HDAC8HDAC3 | |
| SCHEMBL10552640 | 0.85 | HDAC4 (0.62) | HDAC6HDAC4HDAC1HDAC8HDAC3 | |
| SCHEMBL20645579 | 0.85 | HDAC4 (0.61) | HDAC6HDAC4HDAC1HDAC8 | |
| SCHEMBL21175655 | 0.84 | HDAC6 (0.67) | HDAC6HDAC4HDAC1HDAC8HDAC5 | |
| SCHEMBL18824381 | 0.83 | HDAC4 (0.66) | HDAC6HDAC4HDAC1HDAC8 | |
| SCHEMBL21175686 | 0.83 | HDAC6 (0.56) | HDAC6HDAC4HDAC1HDAC8 | |
| SCHEMBL20550193 | 0.82 | HDAC6 (0.55) | HDAC6HDAC4HDAC1HDAC8HDAC3 | |
| SCHEMBL21543796 | 0.82 | HDAC6 (0.73) | HDAC6HDAC4HDAC1HDAC8HDAC5 | |
| SCHEMBL21175730 | 0.82 | HDAC4 (0.55) | HDAC6HDAC4HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11026427-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2021-06-08 | — | — | US | disclosed |
| US-20190223441-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190223441-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | PRF1, NOX3, NOX1 | HDAC6 612/4885HDAC4 1433/4885HDAC1 526/4885 |
| US-11026427-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX3, NOX1 | HDAC6 612/4885HDAC4 1433/4885HDAC1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.